@article{1,
  note = {{U.S. Food & Drug Administration Center for Drug Evaluation and Research. Advancing health through innovation: new drug therapy approvals 2022. Silver Spring, Maryland 2023. Accessed 2023 Jul 24. https://www.fda.gov/media/164429/download?attachment}},
}
@article{2,
  note = {{Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. MAbs. 2023;15(1): 2153410. doi:10.1080/19420862. 2022.2153410.}},
}
@article{3,
  note = {{Cheong HS, Chang JS, Park JM, Byun SM. Affinity enhancement of bispecific antibody against two different epitopes in the same antigen. Biochem Bioph Res Co. 1990;173(3):795–800. doi:10.1016/S0006-291X(05)80857-5.}},
}
@article{4,
  note = {{Yanakieva D, Pekar L, Evers A, Fleischer M, Keller S, Mueller-Pompalla D, Toleikis L, Kolmar H, Zielonka S, Krah S. Beyond bispecificity: controlled fab arm exchange for the generation of antibodies with multiple specificities. MAbs. 2022;14(1): 2018960. doi:10.1080/19420862. 2021.2018960.}},
}
@article{5,
  note = {{Gera N. The evolution of bispecific antibodies. Expert Opin Biol Ther. 2022;22(8):945–49. doi:10.1080/14712598. 2022.2040987.}},
}
@article{6,
  note = {{Underwood DJ, Bettencourt J, Jawad Z. The manufacturing considerations of bispecific antibodies. Expert Opin Biol Ther. 2022;22 (8):1043–65. doi:10.1080/14712598. 2022.2095900.}},
}
@article{7,
  note = {{Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W. et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A. 2010;107 (47):20565–70. doi:10.1073/pnas.1012865107.}},
}
@article{8,
  note = {{Steeland S, Vandenbroucke RE, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016;21(7):1076–113. doi:10.1016/j.drudis. 2016.04.003.}},
}
@article{9,
  note = {{Fan X, Zhuang Q, Yang L, Hao J, Zhao D, Zhao Y, Wang P, Geng D. Preclinical assessment of LCAR-B38M, a novel BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(10):e160. doi:10.1016/j.clml. 2019.09.267.}},
}
@article{10,
  note = {{Zhou J, Shi Z, Shi F, Chen S, Huang C, Li H, Zhang Y, Yi R, Wang H, Li X-Y. et al. Optimization of GPRC5D-targeted CAR T cells (OriCAR-017) for multiple myeloma. J Immunother Cancer BMJ. 2023;11:A370–2. doi:10.1136/jitc-2023-SITC. 2023.0326.}},
}
@article{11,
  note = {{Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJM, Bezabeh BZ, Fleming RL, Dimasi N. et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2016;29 (1):117–29. doi:10.1016/j.ccell. 2015.12.008.}},
}
@article{12,
  note = {{Zhang H, Huang H, Li R, Zhang L, Wang Z, Liang S, Li J, Chen J, Su H, Zheng D. et al. Broadly potent neutralizing bi-specific antibody against SARS CoV-2. Virol Curr Res. 2022;574:1–8. doi:10.1016/j.virol. 2022.07.003.}},
}
@article{13,
  note = {{Xu T, Yin Q, Yan R, Li Q, Wang Y. Method for preventing and/or treating thromboembolic diseases. 2023. WIPO WO2023098637A1.}},
}
@article{14,
  note = {{Chiu M. Multi-specific cMet x EGFR x VEGF antibody for difficult to treat cancers. Cancer Res. 2023;83(7_Supplement): 4494. doi:10.1158/1538-7445. AM2023-4494.}},
}
@article{15,
  note = {{DaSilva JO, Yang K, Perez Bay AE, Andreev J, Ngoi P, Pyles E, Franklin MC, Dudgeon D, Rafique A, Dore A. et al. A biparatopic antibody that modulates MET trafficking exhibits enhanced efficacy compared with parental antibodies in MET-driven tumor models. Clin Cancer Res. 2020;26(6):1408–19. doi:10.1158/1078-0432. CCR-19-2428.}},
}
@article{16,
  note = {{Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J. et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep. 2015;5(1):5. doi:10.1038/srep17943.}},
}
@article{17,
  note = {{Oostindie SC, van der Horst HJ, Kil LP, Strumane K, Overdijk MB, van den Brink EN, van den Brakel JHN, Rademaker HJ, van Kessel B, van den Noort J. et al. DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. Blood Cancer J. 2020;10(3):10. doi:10.1038/s41408-020-0292-7.}},
}
@article{18,
  note = {{Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, Huang TT, Poueymirou WT, Esau L, Meola M. et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111(14):5153–58. doi:10.1073/pnas. 1324022111.}},
}
@article{19,
  note = {{Wei H, Cai H, Jin Y, Wang P, Zhang Q, Lin Y, Wang W, Cheng J, Zeng N, Xu T. et al. Structural basis of a novel heterodimeric Fc for bispecific antibody production. Oncotarget. 2017;8(31):51037–49. doi:10.18632/oncotarget.17558.}},
}
@article{20,
  note = {{Liu Z, Liu Y, Hao X, Zhang X, Guo J. Anti-human-TSLP antibody and use thereof. 2021. WIPO WO2021155634A1.}},
}
@article{21,
  note = {{Sammicheli S, Grandclement C, Labanca V, De Angelis S, Estoppey C, Chimen M, Pouleau B, Suere P, Nallet E, Srivastava A. et al. Preclinical evaluation of ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of AML and T-ALL. Blood. 2022;140 (Supplement 1):6237-6238. doi:10.1182/blood-2022-162201.}},
}
@article{22,
  note = {{Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K, Lord DM, Wei RR, Deng G, Louder M. et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science 2017;358(6359):85–90. doi:10.1126/science. aan8630.}},
}
@article{23,
  note = {{Weisser NE, Sanches M, Escobar-Cabrera E, O’Toole J, Whalen E, Chan PWY, Wickman G, Abraham L, Choi K, Harbourne B. et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023;14: 1394. doi:10.1038/s41467-023-37029-3.}},
}
@article{24,
  note = {{Ugamraj HS, Dang K, Ouisse LH, Buelow B, Chini EN, Castello G, Allison J, Clarke SC, Davison LM, Buelow R. et al. TNB-738, a biparatopic antibody, boosts intracellular NAD + by inhibiting CD38 ecto-enzyme activity. MAbs. 2022;14(1):e2095949. doi:10.1080/19420862. 2022.2095949.}},
}
@article{25,
  note = {{Fischer S, Gӧtze TO, Omlin A, Baird RD, Dawson KM, Zitt C, Arany Z, Tresch G, Fiedler U, Jeger S. et al. A case of sustained tumor regression with MP0274, a novel DARPin therapeutic targeting human epidermal growth factor receptor 2 signaling, in metastatic human epidermal growth factor receptor 2–positive breast cancer after prior trastuzumab and Pertuzumab. JCO Precis Oncol. 2022;6(6):e2200006. doi:10.1200/PO. 22.00006.}},
}
@article{26,
  note = {{Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608. doi:10.1038/s41573-019-0028-1.}},
}
@article{27,
  note = {{Harms BD, Kearns JD, Iadevaia S, Lugovskoy AA. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods. 2014;65 (1):95–104. doi:10.1016/j.ymeth. 2013.07.017.}},
}
@article{28,
  note = {{Neri D, Momo M, Prospero T, Winter G. High-affinity Antigen Binding by Chelating Recombinant Antibodies (CRAbs). J Mol Biol. 1995;246(3):367–73. doi:10.1006/jmbi. 1994.0091.}},
}
@article{29,
  note = {{Robert B, Dorvillius M, Buchegger F, Garambois V, Mani JC, Pugnières M, Mach JP, Pèlegrin A. Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the Carcinoembryonic Antigen (CEA). Int J Cancer. 1999;81(2):285–91. doi:10.1002/(SICI)1097-0215(19990412) 81:2<285:AID-IJC19> 3.0.CO;2-T.}},
}
@article{30,
  note = {{Kim JC, Roh SA, Koo KH, Ryu JH, Hong HK, Oh SJ, Ryu JS, Kim HJ, Bodmer FW. Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery. Int J Cancer. 2002;97(4):542–47. doi:10.1002/ijc.1630.}},
}
@article{31,
  note = {{Henry KA, Nguyen TD, Baral TN, Hussack G, Raphael S, Arbabi-Ghahroudi M, Robert A, Durocher Y, Wu C, Jaramillo ML. et al. Biparatopic single-domain antibodies against Axl achieve ultra-high affinity through intramolecular engagement. Biochem Biophys Res Commun. 2021;562:154–61. doi:10.1016/j.bbrc. 2021.05.030.}},
}
@article{32,
  note = {{Roovers RC, Vosjan MJWD, Laeremans T, El Khoulati R, De Bruin RCG, Ferguson KM, Verkleij AJ, Van Dongen GAMS, Van Bergen En Henegouwen PMP. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer. 2011;129:2013–24. doi:10.1002/ijc.26145.}},
}
@article{33,
  note = {{Fleetwood F, Klint S, Hanze M, Gunneriusson E, Frejd FY, Ståhl S, Löfblom J. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic affibody molecules results in dramatically improved affinity. Sci Rep. 2014;4: 7518. doi:10.1038/ srep07518.}},
}
@article{34,
  note = {{Bradley ME, Dombrecht B, Manini J, Willis J, Vlerick D, De Taeye S, Van Den Heede K, Roobrouck A, Grot E, Kent TC. et al. Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action. Mol Pharmacol. 2015;87(2):251–62. doi:10.1124/mol. 114.094821.}},
}
@article{35,
  note = {{Akiba H, Fujita J, Ise T, Nishiyama K, Miyata T, Kato T, Namba K, Ohno H, Kamada H, Nagata S. et al. Development of a 1: 1-binding biparatopic anti-TNFR2 antagonist by epitope selection. Commun Biol. 2023;6: 987. doi:10.1038/s42003-023-05326-8.}},
}
@article{36,
  note = {{Kast F, Schwill M, Stüber JC, Pfundstein S, Nagy-Davidescu G, Rodríguez JMM, Seehusen F, Richter CP, Honegger A, Hartmann KP. et al. Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action. Nat Commun. 2021;12: 3790. doi:10.1038/s41467-021-23948-6.}},
}
@article{37,
  note = {{Spangler JB, Manzari MT, Rosalia EK, Chen TF, Wittrup KD. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. J Mol Biol. 2012;422(4):532–44. doi:10.1016/j.jmb. 2012.06.014.}},
}
@article{38,
  note = {{Wright MJ, Deonarain MP. Phage display of chelating recombinant antibody libraries. Mol Immunol. 2007;44(11):2860–69. doi:10.1016/j.molimm. 2007.01.026.}},
}
@article{39,
  note = {{Liu J, Wu X, Lin L, Pan H, Wang Y, Li Y, Zhao Y, Wang Z. Bp-Bs, a novel T-cell engaging bispecific antibody with biparatopic Her2 binding, has potent anti-tumor activities. Mol Ther Oncolytics. 2019;14:66–73. doi:10.1016/j.omto. 2019.03.009.}},
}
@article{40,
  note = {{Rennert PD, Dufort FJ, Su L, Sanford T, Birt A, Wu L, Lobb RR, Ambrose C. Anti-CD19 CAR T cells that secrete a biparatopic anti-CLEC12A bridging protein have potent activity against highly aggressive acute myeloid leukemia in vitro and in vivo. Mol Cancer Ther. 2021;20(10):2071–81. doi:10.1158/1535-7163. MCT-20-1030.}},
}
@article{41,
  note = {{Dai Z, Mu W, Zhao Y, Jia X, Liu J, Wei Q, Tan T, Zhou J. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains. Mol Ther. 2021;29(9):2707–22. doi:10.1016/j.ymthe. 2021.07.001.}},
}
@article{42,
  note = {{Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD, Schuller AG, Yuan J, Ospina B, Green J. et al. Inhibition of tumorigenesis driven by different wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci U S A. 2010;107(35):15473–78. doi:10.1073/pnas. 1007428107.}},
}
@article{43,
  note = {{Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Plückthun A. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER 2. Structure. 2013;21(11):1979–91. doi:10.1016/j. str. 2013.08.020.}},
}
@article{44,
  note = {{Stefano JE, Lord DM, Zhou Y, Jaworski J, Hopke J, Travaline T, Zhang N, Wong K, Lennon A, He T. et al. A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms. J Biol Chem. 2020;295(52):18379–89. doi:10.1074/jbc.RA 120.012395.}},
}
@article{45,
  note = {{Gammelgaard OL, Terp MG, Renn C, Labrijn AF, Hamaker O, Nielsen AY, Vever H, Hansen SWK, Gjerstorff MF, Müller CE. et al. Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity. J Immunother Cancer. 2022;10(9):e004554. doi:10.1136/jitc-2022-004554.}},
}
@article{46,
  note = {{Yang Y, Yeh SH, Madireddi S, Matochko WL, Gu C, Pacheco Sanchez P, Ultsch M, De Leon Boenig G, Harris SF, Leonard B. et al. Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members. MAbs. 2019;11(6):996–1011. doi:10.1080/19420862. 2019.1625662.}},
}
@article{47,
  note = {{Shi SY, Lu YW, Liu Z, Stevens J, Murawsky CM, Wilson V, Hu Z, Richards WG, Michaels ML, Zhang J. et al. A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity. J Biol Chem. 2018;293(16):5909–19. doi:10.1074/jbc.RA 118.001752.}},
}
@article{48,
  note = {{Rougé L, Chiang N, Steffek M, Kugel C, Croll TI, Tam C, Estevez A, Arthur CP, Koth CM, Ciferri C. et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 2020;367(6483):1224–30. doi:10.1126/ science.aaz9356.}},
}
@article{49,
  note = {{Bogen JP, Carrara SC, Fiebig D, Grzeschik J, Hock B, Kolmar H. Expeditious generation of biparatopic common light chain antibodies via chicken immunization and yeast display screening. Front Immunol. 2020;11: 606878. doi:10.3389/fimmu. 2020.606878.}},
}
@article{50,
  note = {{Kasturirangan S, Rainey GJ, Xu L, Wang X, Portnoff A, Chen T, Fazenbaker C, Zhong H, Bee J, Zeng Z. et al. Targeted Fcγ receptor (FcγR)-mediated clearance by a biparatopic bispecific antibody. J Biol Chem. 2017;292(10):4361–70. doi:10.1074/jbc.M 116.770628.}},
}
@article{51,
  note = {{Cano-Garrido O, Álamo P, Sánchez-García L, Falgàs A, Sánchez-Chardi A, Serna N, Parladé E, Unzueta U, Roldán M, Voltà-Durán E. et al. Biparatopic protein nanoparticles for the precision therapy of CXCR4+ cancers. Cancers. 2021;13(12): 2929. doi:10.3390/can cers13122929.}},
}
@article{52,
  note = {{Emmerson CD, van der Vlist Els J, Braam MR, Vanlandschoot P, Merchiers P, de Haard Hans JW, Verrips CT, van Bergen En Henegouwen MP, Dolk E, Bansal GP. Enhancement of polymeric immunoglobulin receptor transcytosis by biparatopic VHH. PLOS ONE. 2011;6(10):e26299. doi:10.1371/journal.pone.0026299.}},
}
@article{53,
  note = {{Cheng J, Liang M, Carvalho MF, Tigue N, Faggioni R, Roskos LK, Vainshtein I. Molecular mechanism of HER2 rapid internalization and redirected trafficking induced by anti-HER2 biparatopic antibody. Antibodies. 2020;9(3):1–21. doi:10.3390/antib9030049.}},
}
@article{54,
  note = {{Benedetti F, Stadlbauer K, Stadlmayr G, Rüker F, Wozniak-Knopp G. A tetravalent biparatopic antibody causes strong HER2 internalization and inhibits cellular proliferation. Life. 2021;11 (11): 1157. doi:10.3390/life11111157.}},
}
@article{55,
  note = {{Oganesyan V, Peng L, Bee JS, Li J, Perry SR, Comer F, Xu L, Cook K, Senthil K, Clarke L. et al. Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody. J Biol Chem. 2018;293(22):8439–48. doi:10.1074/jbc.M 117.818013.}},
}
@article{56,
  note = {{DaSilva JO, Yang K, Surriga O, Nittoli T, Kunz A, Franklin MC, Delfino FJ, Mao S, Zhao F, Giurleo JT. et al. A biparatopic antibody– drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. Mol Cancer Ther. 2021;20(10):1966–76. doi:10.1158/1535-7163. MCT-21-0009.}},
}
@article{57,
  note = {{Barnscher SD, Rojas AH, Hamblett KJ, Escalante N. Zanidatamab zovodotin. (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer. Cancer Res. 2023;83(7_Supplement): 2633. doi:10.1158/1538-7445. AM2023-2633.}},
}
@article{58,
  note = {{Ab O, Bartle LM, Lanieri L, Ponte JF, Qiu Q, Sikka S, Costoplus JA, Deats W, Yoder NC, Widdison WC. et al. IMGN151 - a next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression. Cancer Res. 2020;80(16_Supplement): 2890. doi:10.1158/ 1538-7445. AM2020-2890.}},
}
@article{59,
  note = {{Caskey M, Klein F, Nussenzweig MC. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat Med. 2019;25(4):547–53. doi:10.1038/s41591-019-0412-8.}},
}
@article{60,
  note = {{Cho H, Kay Gonzales-Wartz K, Huang D, Yuan M, Peterson M, Liang J, Beutler N, Torres JL, Cong Y, Postnikova E. et al. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Sci Transl Med. 2021;13(616):1–19. doi:10.1126/scitranslmed.abj5413.}},
}
@article{61,
  note = {{Ahn S, Li J, Sun C, Gao K, Hirabayashi K, Li H, Savoldo B, Liu R, Dotti G. Cancer immunotherapy with T cells carrying bispecific receptors that mimic antibodies. Cancer Immunol Res. 2019;7 (5):773–83. doi:10.1158/2326-6066. CIR-18-0636.}},
}
@article{62,
  note = {{Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M. Ciltacabtagene autoleucel, an anti– Bcell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2022;41(6):1265–74. doi:10.1200/JCO. 22.00842.}},
}
@article{63,
  note = {{Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, Wang D, Luo X, Cui J, Huang S. et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023;10(2):e107–16. doi:10.1016/S2352- 3026(22)00372-6.}},
}
@article{64,
  note = {{Sia H, Tan PT, Richter J, Ho PJ, Cochrane T, Quach H, Dhakal B, Proscurshim I, Jiang T, Mancino E. et al. A phase 1/2, first-inhuman, multicenter, open-label, dose escalation and dose-expansion study of single-agent ISB 1442 in patients with relapsed/ refractory multiple myeloma. Blood. 2022;140 (Supplement 1):10182-10184. doi:10.1182/blood-2022-157585.}},
}
@article{65,
  note = {{Fiedler U, Metz C, Zitt C, Bessey R, Béhé M, Blanc A, Schibli R, Dolado I, Herbst J, Dawson K. et al. Pre-clinical antitumor activity, tumor localization, and pharmacokinetics of MP0274, an apoptosis inducing, biparatopic HER2-targeting DARPin®. Cancer Res. 2017;77(4_Supplement):P4-21-18. doi:10.1158/1538-7445. SABCS16-P4-21-18.}},
}
@article{66,
  note = {{Wang P, Guo K, Peng J, Sun J, Xu T. JSKN003, A novel biparatopic anti-HER2 antibody-drug conjugate, exhibits potent antitumor efficacy. Antib Ther. 2023;6(Supplement_1):tbad 014 009. doi:10.1093/abt/tbad 014 009.}},
}
@article{67,
  note = {{De Santis R. Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy. MAbs. 2020;12: 1725346. doi:10.1080/19420862. 2020.1725346.}},
}
@article{68,
  note = {{Prokofyev AV, Kharatian NG, Krendeleva EA, Shitikova VO, Shchemeleva MA, Anikina AV, Nazarenko OV, Evstrateva AV, Sozonova AA, Cherkasov AV. et al. Bispecific antibody that specifically binds to subdomains IV and II of the extracellular domain of human her 2. 2019. WIPO WO2019190359A1.}},
}
@article{69,
  note = {{Zhang S, Li J, Su C, Huang J. Anti-human-HER2 humanized bispecific antibody and use thereof. 2023. WIPO WO2023221946A1.}},
}
@article{70,
  note = {{Yan R, Li Q, Xu T, Yu J, Wang Y. Method for preventing and/or treating blood coagulation factor XI-associated diseases. 2023. WIPO WO2023197992A1.}},
}
@article{71,
  note = {{Lyu X, Zhao Q, Hui J, Wang T, Lin L, Wang K, Zhang J, Shentu X, Dall’Acqua WF, Damschroder MM. et al. The global landscape of approved antibody therapies. Antib Ther. 2022;5(4):233–57. doi:10.1093/abt/tbac021.}},
}
@article{72,
  note = {{Mullard A. 2022 FDA drug approvals. Nat Rev Drug Discov. 2023;22(2):83–88. doi:10.1038/d41573-023-00001-3.}},
}
@article{73,
  note = {{Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Di-éras V, Hegg R, Im S-A, Shaw Wright G. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21. doi:10.1056/ NEJMoa1809615.}},
}
@article{74,
  note = {{Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Di-éras V, Henschel V, Molinero L, Chui SY. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, doubleblind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(1): 44–59. doi:10.1016/S1470-2045(19)30689-8.}},
}
@article{75,
  note = {{Lyu X, Wang K, Lin L, Wang T, Zhang J, Shentu X, Zhao Q. Approved antibody therapies in the post-pandemic era: 2022-2023 updates. Antib Ther. 2024;7(1):1–27. doi:10.1093/abt/tbad029.}},
}
@article{76,
  note = {{Merck & Co. Merck and Eisai provide update on phase 3 LEAP-008 trial evaluating KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) for the first-line treatment of patients with metastatic non-small cell lung cancer. 2023 Dec 8. https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-leap-008-trial-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell/}},
}
@article{77,
  note = {{Merus NV. Merus provides corporate update and reports third quarter 2023 financial results. 2023 Nov 7. https://ir.merus.nl/news-releases/news-release-details/merus-provides-corporate-update-and-reports-third-quarter-2023}},
}
@article{78,
  note = {{Johnson & Johnson. CARVYKTI® (ciltacabtagene autoleucel) 28- month follow-up data from CARTITUDE-4 study show substantial prolongation of progression-free survival in patients with relapsed or refractory multiple myeloma. 2024 May 31. https://www.jnj.com/media-center/press-releases/carvykti-ciltacabtagene-autoleucel-28-month-follow-up-data-from-cartitude-4-study-show-substantial-prolongation-of-progression-free-survival-in-patients-with-relapsed-or-refractory-multiple-myeloma}},
}
@article{79,
  note = {{Legend Biotech. Legend Biotech announces positive results from phase 2 trial of ciltacabtagene autoleucel (cilta-cel) in patients with relapsed or refractory multiple myeloma (CARTITUDE-1). 2020 Dec 5. https://legendbiotech.com/legend-news/legend-biotech-announces-positive-results-from-phase-2-trial-of-ciltacabtagene-autoleucel-cilta-cel-in-patients-with-relapsed-or-refractory-multiple-myeloma-cartitude-1/}},
}
@article{80,
  note = {{Merck & Co. Merck provides update on phase 3 LEAP-007 trial evaluating KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) as first-line treatment for patients with metastatic non-small cell lung cancer. 2024 Apr 1. https://www.merck.com/news/merck-provides-update-on-phase-3-leap-007-trial-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-as-first-line-treatment-for-patients-with-metastatic-non-small-cell-lung-cancer/}},
}
@article{81,
  note = {{Zymeworks Inc. Zymeworks announces updated results from phase 1 study of zanidatamab (ZW25) in patients with HER2-expressing cancers. 2020 Jan 20. https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-updated-results-phase-1-study-zanidatamab-zw25}},
}
@article{82,
  note = {{Roche. Roche announces positive results from phase III study of Perjeta plus Herceptin and chemotherapy as adjuvant treatment for people with HER2-positive early breast cancer. 2017 Mar 2. https://www.roche.com/media/releases/med-cor-2017-03-02.htm}},
}
@article{83,
  note = {{Zymeworks Inc. Zymeworks announces positive top-line results from pivotal phase 2b HERIZON-BTC-01 study of zanidatamab in patients with previously treated HER2-amplified biliary tract cancer. 2022 Dec 19. https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-positive-top-line-results-pivotal-phase-2b}},
}
@article{84,
  note = {{Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16(7):677–81. doi:10.1038/nbt0798-677.}},
}
@article{85,
  note = {{Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Ince NS, Fu NH. et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 2013;153(1):126–38. doi:10.1016/j. cell. 2013.03.018.}},
}
@article{86,
  note = {{Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY. et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181(4):894–904.e9. doi:10.1016/j.cell. 2020.03.045.}},
}
@article{87,
  note = {{Finlay WJJ, Bloom L, Cunningham O. Biparatopic antibodies: a new class of antibody-based therapeutics. In: Almagro JC, editor. Antibody engineering. New York, NY: Springer; 2018. p. 119–141.}},
}
@article{88,
  note = {{Oostindie SC, Lazar GA, Schuurman J, Parren PWHI. Avidity in antibody effector functions and biotherapeutic drug design. Nat Rev Drug Discov. 2022;21(10):715–35. doi:10.1038/s41573-022-00504-x.}},
}
@article{89,
  note = {{Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs. 2012;4(6):653–63. doi:10.4861/ mabs.21379.}},
}
@article{90,
  note = {{Spiess C, Zhai Q, Carter PJ. Alternative molecular formats for bispecific antibodies. Mol Immunol. 2015;67(2 Pt A):95–106. doi:10.1016/j.molimm. 2015.01.003.}},
}
@article{91,
  note = {{Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212. doi:10.1080/19420862. 2016.1268307.}},
}
@article{92,
  note = {{Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S. et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011;108(27):11187–92. doi:10.1073/pnas.1019002108.}},
}
@article{93,
  note = {{Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJR. et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343(6176):1260–63. doi:10.1126/science. 1248943.}},
}
